myoscience
Jeffrey Gold Joins myoscience as President and Chief Operating Officer
DGAP-News: myoscience / 23.04.2014 / 14:00 --------------------------------------------------------------------- REDWOOD CITY, Calif., 2014-04-23 14:00 CEST (GLOBE NEWSWIRE) -- myoscience, inc. is pleased to announce the addition of Jeffrey Gold to the team as President and Chief Operating Officer (COO). Mr. Gold is an accomplished executive, having held posts as Chief Executive for Velomedix and CryoVascular Systems as well as Chief Operating Officer for CardioThoracic Systems. 'Jeff's leadership and extensive experience driving operational excellence makes him an exceptional addition to myoscience as we expand our global commercial presence in both aesthetic and therapeutic channels,' said Clint Carnell, CEO of myoscience. Mr. Gold was most recently the President & CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest. Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices. 'I am thrilled to be joining myoscience at such an exciting point in their growth,' said Gold. 'My previous experience and the current needs of the company align perfectly and I look forward to guiding the business towards further success.' ABOUT MYOSCIENCE Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy(TM), the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera:o system. The iovera:o system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com. The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581 (c) 2014 myoscience. All rights reserved. iovera* and Focused Cold Therapy are trademarks of myoscience. CONTACT: 1600 Seaport Blvd., Ste. 450 / Redwood City, CA Tel: 650.474.2600 / iovera.com MEDIA RELATIONS Peter Osborne / posborne@myoscience.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 23.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: myoscience United States ISIN: US9902131674 End of News DGAP News-Service --------------------------------------------------------------------- 264244 23.04.2014
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found